TY - JOUR
T1 - VEGF-targeted magnetic nanoparticles for MRI visualization of brain tumor
AU - Abakumov, Maxim A.
AU - Nukolova, Natalia V.
AU - Sokolsky-Papkov, Marina
AU - Shein, Sergey A.
AU - Sandalova, Tatiana O.
AU - Vishwasrao, Hemant M.
AU - Grinenko, Nadezhda F.
AU - Gubsky, Iliya L.
AU - Abakumov, Artem M.
AU - Kabanov, Alexander V.
AU - Chekhonin, Vladimir P.
N1 - Publisher Copyright:
© 2015 Elsevier Inc..
PY - 2015/5/1
Y1 - 2015/5/1
N2 - This work is focused on synthesis and characterization of targeted magnetic nanoparticles as magnetic resonance imaging (m{cyrillic}RI) agents for in vivo visualization of gliomas. Ferric oxide (Fe3O4) cores were synthesized by thermal decomposition and coated with bovine serum albumin (BSA) to form nanoparticles with Deff of 53±9nm. The BSA was further cross-linked to improve colloidal stability. Monoclonal antibodies against vascular endothelial growth factor (mAbVEGF) were covalently conjugated to BSA through a polyethyleneglycol linker. Here we demonstrate that 1) BSA coated nanoparticles are stable and non-toxic to different cells at concentration up to 2.5mg/mL; 2) conjugation of monoclonal antibodies to nanoparticles promotes their binding to VEGF-positive glioma s{cyrillic}6 cells in vitro; 3) targeted nanoparticles are effective in MRI visualization of the intracranial glioma. Thus, mAbVEGF-targeted BSA-coated magnetic nanoparticles are promising MRI contrast agents for glioma visualization. From the Clinical Editor: This work focuses on synthesis and characterization of targeted magnetic nanoparticles as magnetic resonance imaging (m{cyrillic}RI) agents for in vivo visualization of gliomas. The authors utilize the fact that high-grade gliomas have extensive areas of necrosis and hypoxia, which results in increased secretion of angiogenesis vascular endothelial growth factor (VEGF). Monoclonal antibodies against vascular endothelial growth factor (mAbVEGF) were covalently conjugated to crosslinked BSA coated ferric oxide (Fe3O4) nanoparticles. The results show that these targeted nanoparticles are effective in MRI visualization of the intracranial glioma and may provide a new and promising contrast agent.
AB - This work is focused on synthesis and characterization of targeted magnetic nanoparticles as magnetic resonance imaging (m{cyrillic}RI) agents for in vivo visualization of gliomas. Ferric oxide (Fe3O4) cores were synthesized by thermal decomposition and coated with bovine serum albumin (BSA) to form nanoparticles with Deff of 53±9nm. The BSA was further cross-linked to improve colloidal stability. Monoclonal antibodies against vascular endothelial growth factor (mAbVEGF) were covalently conjugated to BSA through a polyethyleneglycol linker. Here we demonstrate that 1) BSA coated nanoparticles are stable and non-toxic to different cells at concentration up to 2.5mg/mL; 2) conjugation of monoclonal antibodies to nanoparticles promotes their binding to VEGF-positive glioma s{cyrillic}6 cells in vitro; 3) targeted nanoparticles are effective in MRI visualization of the intracranial glioma. Thus, mAbVEGF-targeted BSA-coated magnetic nanoparticles are promising MRI contrast agents for glioma visualization. From the Clinical Editor: This work focuses on synthesis and characterization of targeted magnetic nanoparticles as magnetic resonance imaging (m{cyrillic}RI) agents for in vivo visualization of gliomas. The authors utilize the fact that high-grade gliomas have extensive areas of necrosis and hypoxia, which results in increased secretion of angiogenesis vascular endothelial growth factor (VEGF). Monoclonal antibodies against vascular endothelial growth factor (mAbVEGF) were covalently conjugated to crosslinked BSA coated ferric oxide (Fe3O4) nanoparticles. The results show that these targeted nanoparticles are effective in MRI visualization of the intracranial glioma and may provide a new and promising contrast agent.
KW - Glioblastoma
KW - Iron oxide nanoparticles
KW - MRI
KW - VEGF
UR - http://www.scopus.com/inward/record.url?scp=84929380237&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84929380237&partnerID=8YFLogxK
U2 - 10.1016/j.nano.2014.12.011
DO - 10.1016/j.nano.2014.12.011
M3 - Article
C2 - 25652902
AN - SCOPUS:84929380237
SN - 1549-9634
VL - 11
SP - 825
EP - 833
JO - Nanomedicine: Nanotechnology, Biology, and Medicine
JF - Nanomedicine: Nanotechnology, Biology, and Medicine
IS - 4
ER -